​

David Bermudes, Ph.D

David Bermudes, Ph.D. is an Associate Professor at California State University, Northridge. He has over 60 scientific publications

and 40 issued US patents. He is a co-inventor of the original tumor-targeted Salmonella technology from Yale University and led the genetic engineering of VNP20009 and TAPET-CD at Vion Pharmaceuticals which were used in six clinical trials in humans.  

​

​

Steven M Hoffberg

Coming soon.

​

​

Michael Summers

Dr. Summers’ laboratory investigates the problem of how bacteria regulate adaptive alterations of their cell morphology and physiology in response to environmental changes.  His research focuses on identification of genes involved in cellular differentiation.  His lab has developed plasmid vectors to report gene transcription and have tested them for specific expression using known promoters. 

​

​

David Quintero, MS, CLS

David Quintero is a co-inventor of the protease inhibitor detection assay as well as the Theobald’s lead candidate chimeric toxin that targets EGFR overexpressing cells. David’s scientific expertise is in genetic engineering of E. coli and Salmonella as well as medical microbiology and diagnostic testing.  He is currently the head of COVID-19 testing at the Los Angeles County Medical Facility.

​

​

Douglas H. Thamm, VMD, DACVIM (Oncology)

Dr. Thamm is the Barbara Cox Anthony Professor of Oncology and Director of Clinical Research at the Colorado State University Flint Animal Cancer Center. He is also a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. He has authored over 150 peer-reviewed publications and 20 book chapters in veterinary and basic cancer research, is Co-Editor for the most recent edition of  the textbook Withrow and MacEwen’s Small Animal Clinical Oncology, and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology.  His clinical and research interests include novel targeted therapies for animal and human cancer and ways to integrate these therapies with existing treatment.

 

​

David Schackelford, Ph.D.

The Shackelford lab is located in the heart of UCLA’s David Geffen School of Medicine in Los Angeles. His lab works at the intersection of signal transduction and metabolism in cancer in order to identify the molecular and metabolic basis of tumorigenesis. His lab uses a range of technologies that include PET imaging, microscopy, mass spectrometry and biochemistry that allows us to visually and functionally profile tumors as they progress and evolve during tumorigenesis. His work integrate both basic and translational research platforms in order to develop more effective strategies to improve detection, diagnosis and treatment for cancer patients.